The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,340
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
Angeli, J. P. F., Krysko, D. V., & Conrad, M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0149-1 · Cited by 1,275
Quantitative Proteomics of the Cancer Cell Line Encyclopedia
Nusinow, D. P., Szpyt, J., Ghandi, M., Rose, C. M., McDonald, E. R., Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D. K., Jedrychowski, M., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.023 · Cited by 957
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 890
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 697
The Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 659
Cano-Gamez, E., & Trynka, G. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00424 · Cited by 613
Bock, C., Datlinger, P., Chardon, F. M., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00093-4 · Cited by 641
Self-citationAdvances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 603
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Open Targets Platform: supporting systematic drug–target identification and prioritisation
Ochoa, D., Hercules, A., Carmona, M., Süveges, D., Gonzalez‐Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho‐Silva, D., Spitzer, M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1027 · Cited by 487
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 490
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458
A metastasis map of human cancer cell lines
Jin, X., Demere, Z., Nair, K., Ali, A., Ferraro, G. B., Natoli, T. E., Deik, A., Petronio, L., Tang, A. A., Zhu, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2969-2 · Cited by 436
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00441-w · Cited by 457
Clinical actionability of molecular targets in endometrial cancer
Urick, M. E., & Bell, D. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0177-x · Cited by 405
Dempster, J. M., Boyle, I., Vázquez, F., Root, D. E., Boehm, J. S., Hahn, W. C., Tsherniak, A., & McFarland, J. M. (2021) · Genome biology · doi:10.1186/s13059-021-02540-7 · Cited by 433
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Zatreanu, D. A., Robinson, H. M. R., Alkhatib, O., Boursier, M. L., Finch, H., Geo, L., Grande, D., Grinkevich, V. V., Heald, R. A., Langdon, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23463-8 · Cited by 384
Huang, C. L., Chen, L., Savage, S. R., Eguez, R. V., Dou, Y., Li, Y., Leprevost, F. D. V., Jaehnig, E. J., Lei, J. T., Wen, B., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.007 · Cited by 361
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis
Bosch, B., DeJesus, M. A., Poulton, N. C., Zhang, W., Engelhart, C. A., Zaveri, A., Lavalette, S., Ruecker, N., Trujillo, C., Wallach, J. B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.033 · Cited by 316
METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis
Su, R. J., Dong, L., Li, Y., Gao, M., He, P. C., Liu, W., Wei, J., Zhao, Z., Gao, L., Han, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00835-2 · Cited by 350
Machine learning for multi-omics data integration in cancer
Cai, Z., Poulos, R. C., Liu, J., & Zhong, Q. (2022) · iScience · doi:10.1016/j.isci.2022.103798 · Cited by 366
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities
Han, K., Pierce, S. E., Li, A., Spees, K., Anderson, G. R., Seoane, J. A., Lo, Y.-H., Dubreuil, M., Olivas, M., Kamber, R. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2099-x · Cited by 311
Pathway Commons 2019 Update: integration, analysis and exploration of pathway data
Rodchenkov, I. V., Babur, Ö., Luna, A., Aksoy, B. A., Wong, J. V., Fong, D., Franz, M., Siper, M. C., Cheung, M., Wrana, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz946 · Cited by 318
Integrated cross-study datasets of genetic dependencies in cancer
Pacini, C., Dempster, J. M., Boyle, I., Gonçalves, E., Najgebauer, H., Karakoç, E., van der Meer, D. J., Barthorpe, A. S., Lightfoot, H. W., Jaaks, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21898-7 · Cited by 299
Self-citationTranslational genomics and recent advances in oral squamous cell carcinoma
Chai, A. W. Y., Lim, K. P., & Cheong, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.011 · Cited by 300
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 300
A new era in functional genomics screens
Przybyla, L., & Gilbert, L. A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00409-w · Cited by 281
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13805-y · Cited by 254
Self-citationBock, C., Datlinger, P., Chardon, F. M., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00098-7 · Cited by 264
Self-citationChehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Mechanisms of APOBEC3 mutagenesis in human cancer cells
Petljak, M., Dananberg, A., Chu, K., Bergstrom, E. N., Striepen, J., von Morgen, P., Chen, Y., Shah, H., Sale, J. E., Alexandrov, L. B., et al. (2022) · Nature · doi:10.1038/s41586-022-04972-y · Cited by 252
Pan-cancer proteomic map of 949 human cell lines
Gonçalves, E., Poulos, R. C., Cai, Z., Barthorpe, S., Manda, S. S., Lucas, N., Beck, A., Bucio-Noble, D., Dausmann, M., Hall, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.010 · Cited by 239
Self-citationIdentifying chemogenetic interactions from CRISPR screens with drugZ
Colic, M., Wang, G., Zimmermann, M., Mascall, K. S., McLaughlin, M. E., Bertolet, L. L., Lenoir, W. F., Moffat, J., Angers, S., Durocher, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0665-3 · Cited by 211
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
Design and analysis of CRISPR–Cas experiments
Hanna, R. E., & Doench, J. G. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0490-7 · Cited by 216
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Setton, J. S., Zinda, M. J., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M. T., Reis-Filho, J. S., & Powell, S. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1503 · Cited by 214
Liu, Q., & Xie, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 205
Repeat expansions confer WRN dependence in microsatellite-unstable cancers
van Wietmarschen, N., Sridharan, S., Nathan, W. J., Tubbs, A., Chan, E. M., Callén, E., Wu, W., Belinky, F., Tripathi, V., Wong, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2769-8 · Cited by 209
McFarland, J. M., Paolella, B. R., Warren, A., Geiger-Schuller, K., Shibue, T., Rothberg, M., Kuksenko, O., Colgan, W. N., Jones, A., Chambers, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17440-w · Cited by 173
A unified model for the G1/S cell cycle transition
Hume, S., Dianov, G. L., & Ramadan, K. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1002 · Cited by 207
Targeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P. A., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 188
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 193
Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles
Michlits, G., Jude, J., Hinterndorfer, M., de Almeida, M., Vainorius, G., Hubmann, M., Neumann, T., Schleiffer, A., Burkard, T. R., Fellner, M., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0850-8 · Cited by 154
Zhang, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30064 · Cited by 191
Jin, H., Zhang, C., Zwahlen, M., von Feilitzen, K., Karlsson, M., Shi, M., Yuan, M., Song, X., Li, X., Yang, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41132-w · Cited by 188
CRL4AMBRA1 is a master regulator of D-type cyclins
Simoneschi, D., Róna, G., Zhou, N., Jeong, Y., Jiang, S., Milletti, G., Arbini, A., O’sullivan, A., Wang, A. A., Nithikasem, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03445-y · Cited by 166
A first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Looking beyond the hype: applied AI and machine learning in translational medicine
Toh, T. S., Dondelinger, F., & Wang, D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.027 · Cited by 159
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Xiong, Y., Zhong, Y., Yim, H., Yang, X., Park, K.-S., Xie, L., Poulikakos, P. I., Han, X., Xiong, Y., Chen, X., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09255 · Cited by 154
Ito, T., Young, M. J., Li, R., Jain, S. S., Wernitznig, A., Krill-Burger, J. M., Lemke, C. T., Monducci, D., Rodriguez, D. J., Chang, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00967-z · Cited by 154
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
Replogle, J. M., Bonnar, J. L., Pogson, A. N., Liem, C. R., Maier, N. K., Ding, Y., Russell, B. J., Wang, X., Leng, K., Guna, A., et al. (2022) · eLife · doi:10.7554/elife.81856 · Cited by 158
A new wave of innovations within the DNA damage response
Li, Q., Qian, W., Zhang, Y., Hu, L., Chen, S., & Xia, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01548-8 · Cited by 166
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Ferretti, S., Hamon, J., de Kanter, R., Scheufler, C., Andraos, R., Barbé, S., Bechter, E., Blank, J., Bordas, V., Dammassa, E., et al. (2024) · Nature · doi:10.1038/s41586-024-07350-y · Cited by 152
Artificial intelligence in early drug discovery enabling precision medicine
Boniolo, F., Dorigatti, E., Ohnmacht, A. J., Saur, D., Schubert, B., & Menden, M. P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1918096 · Cited by 147
Hu, Z., Yuan, J., Long, M., Jiang, J., Zhang, Y., Zhang, T., Xu, M., Fan, Y., Tanyi, J. L., Montone, K. T., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00282-w · Cited by 144
Genetic screens in isogenic mammalian cell lines without single cell cloning
DeWeirdt, P. C., Sangree, A. K., Hanna, R. E., Sanson, K. R., Hegde, M., Strand, C., Persky, N. S., & Doench, J. G. (2020) · Nature Communications · doi:10.1038/s41467-020-14620-6 · Cited by 138
CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma
Liu, S. J., Malatesta, M., Lien, B. V., Saha, P., Thombare, S. S., Hong, S. J., Pedraza, L., Koontz, M., Seo, K., Horlbeck, M. A., et al. (2020) · Genome biology · doi:10.1186/s13059-020-01995-4 · Cited by 144
CRISPR screens in physiologic medium reveal conditionally essential genes in human cells
Rossiter, N. J., Huggler, K. S., Adelmann, C. H., Keys, H. R., Soens, R. W., Sabatini, D. M., & Cantor, J. R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.005 · Cited by 138
Kim, E., & Hart, T. (2021) · Genome Medicine · doi:10.1186/s13073-020-00809-3 · Cited by 131
Pan-cancer proteogenomics expands the landscape of therapeutic targets
Savage, S. R., Yi, X., Lei, J. T., Wen, B., Zhao, H., Liao, Y., Jaehnig, E. J., Somes, L. K., Shafer, P. W., Lee, T. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.039 · Cited by 137
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Baltgalvis, K. A., Lamb, K. N., Symons, K. T., Wu, C.-C., Hoffman, M. A., Snead, A. N., Song, X., Glaza, T., Kikuchi, S., Green, J. C., et al. (2024) · Nature · doi:10.1038/s41586-024-07318-y · Cited by 134
Picco, G., Chen, E. D., García‐Alonso, L., Behan, F. M., Gonçalves, E., Bignell, G. R., Matchan, A., Fu, B., Banerjee, R., Anderson, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09940-1 · Cited by 128
Self-citationBaker, N., Catta‐Preta, C. M. C., Neish, R., Sádlová, J., Powell, B., Alves‐Ferreira, E. V. C., Geoghegan, V., Carnielli, J. B. T., Newling, K., Hughes, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21360-8 · Cited by 130
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
Tello‐Lafoz, M., Srpan, K., Sanchez, E. E., Hu, J. Y., Remšík, J., Romin, Y., Calò, A., Hoen, D. R., Bhanot, U. K., Morris, L. G. T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.020 · Cited by 129
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Wu, Q., Nie, D. Y., Ba-Alawi, W., Ji, Y., Zhang, Z., Cruickshank, J., Haight, J., Ciamponi, F. E., Chen, J., Duan, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01024-4 · Cited by 132
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, J. A., Klomp, J. E., Stalnecker, C. A., Bryant, K. L., Edwards, A. C., Drizyte‐Miller, K., Hibshman, P. S., Diehl, J. N., Lee, Y. S., Morales, A. J., et al. (2024) · Science · doi:10.1126/science.adk0775 · Cited by 139
Combinatorial CRISPR screen identifies fitness effects of gene paralogues
Thompson, N., Ranzani, M., van der Weyden, L., Iyer, V., Offord, V., Droop, A., Behan, F. M., Gonçalves, E., Speak, A. O., Iorio, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21478-9 · Cited by 120
Self-citationAdam, S., Rossi, S. E., Moatti, N., De Marco Zompit, M., Xue, Y., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00266-w · Cited by 121
canSAR: update to the cancer translational research and drug discovery knowledgebase
Coker, E. A., Mitsopoulos, C., Tym, J. E., Komianou, A., Kannas, C. C., Micco, P. D., Villasclaras-Fernández, E. D., Özer, B., Antolín, A. A., Workman, P., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1129 · Cited by 121
Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H. W., Yang, W., van der Meer, D. J., Shepherd, R., Pignatelli, M., Iorio, F., & Garnett, M. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa882 · Cited by 120
Self-citationOvarian cancer-derived IL-4 promotes immunotherapy resistance
Mollaoglu, G., Tepper, A., Falcomatà, C., Potak, H. T., Pia, L., Amabile, A., Mateus-Tique, J., Rabinovich, N., Park, M. D., LaMarche, N. M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.006 · Cited by 123
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
Niu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., Zhan, S., Chen, D., Bu, X., Liu, P., et al. (2021) · Hepatology · doi:10.1002/hep.31846 · Cited by 115
Picco, G., Cattaneo, C. M., van Vliet, E. J., Crisafulli, G., Rospo, G., Consonni, S., Vieira, S. F., Sánchez-Rodríguez, I., Cancelliere, C., Banerjee, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1508 · Cited by 112
Self-citationAregger, M., Lawson, K. A., Billmann, M., Costanzo, M., Tong, A. H. Y., Chan, K., Rahman, M., Brown, K. R., Ross, C., Usaj, M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0211-z · Cited by 115
Shemesh, N., Jubran, J., Dror, S., Simonovsky, E., Basha, O., Argov, C. M., Hekselman, I., Abu‐Qarn, M., Vinogradov, E., Mauer, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22369-9 · Cited by 117
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Seong, B. K. A., Dharia, N. V., Lin, S., Donovan, K. A., Chong, S., Robichaud, A. L., Conway, A. S., Hamze, A., Ross, L. S., Alexe, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.003 · Cited by 118
Dreßler, L., Bortolomeazzi, M., Keddar, M. R., Mišetić, H., Sartini, G., Acha‐Sagredo, A., Montorsi, L., Wijewardhane, N., Repana, D., Nulsen, J., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02607-z · Cited by 119
Boullosa, L. F., Loenhout, J. V., Flieswasser, T., Waele, J. D., Hermans, C., Lambrechts, H. A. J., Cuypers, B., Laukens, K., Bartholomeus, E., Siozopoulou, V., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101949 · Cited by 111
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Fang, Y., Wang, S., Han, S., Zhao, Y., Yu, C., Liu, H., & Li, N. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.003 · Cited by 113
Predicting and affecting response to cancer therapy based on pathway-level biomarkers
Ben‐Hamo, R., Berger, A. J., Gavert, N. S., Miller, M. L., Pines, G., Oren, R., Pikarsky, E., Benes, C. H., Neuman, T., Zwang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17090-y · Cited by 110
Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How
Bröer, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176156 · Cited by 116
CRISPR-based therapeutics: current challenges and future applications
Modell, A. E., Lim, D., Nguyen, T. M., Sreekanth, V., & Choudhary, A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.012 · Cited by 114
Pacini, C., Duncan, E., Gonçalves, E., Gilbert, J. G. R., Bhosle, S. G., Horswell, S. D., Karakoç, E., Lightfoot, H. W., Curry, E. W., Muyas, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.016 · Cited by 116
Self-citationDede, M., McLaughlin, M. E., Kim, E., & Hart, T. (2020) · Genome biology · doi:10.1186/s13059-020-02173-2 · Cited by 102
Ferroptosis regulation by the NGLY1/NFE2L1 pathway
Forcina, G. C., Pope, L. E., Murray, M. B., Dong, W., Abu-Remaileh, M., Bertozzi, C. R., & Dixon, S. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2118646119 · Cited by 103
The Mechanism of Ferroptosis and Applications in Tumor Treatment
Lin, X., Ping, J., Wen, Y., & Wu, Y. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01061 · Cited by 107
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 108
CRISPR screens in plants: approaches, guidelines, and future prospects
Gaillochet, C., Develtere, W., & Jacobs, T. B. (2021) · The Plant Cell · doi:10.1093/plcell/koab099 · Cited by 102
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L. M., Wirth, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317856 · Cited by 105
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
Gonçalves, E., Segura‐Cabrera, A., Pacini, C., Picco, G., Behan, F. M., Jaaks, P., Coker, E. A., van der Meer, D., Barthorpe, A. S., Lightfoot, H. W., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199405 · Cited by 106
Self-citationBonagas, N., Gustafsson, N., Henriksson, M., Marttila, P., Gustafsson, R., Wiita, E., Borhade, S. R., Green, A. C., Vallin, K. S. A., Sarno, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00331-y · Cited by 104
Corso, S., Isella, C., Bellomo, S. E., Apicella, M., Durando, S., Migliore, C., Ughetto, S., D’Errico, L., Menegon, S., Moya-Rull, D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1166 · Cited by 99
Cancer research needs a better map
Boehm, J. S., Garnett, M. J., Adams, D. J., Francies, H. E., Golub, T. R., Hahn, W. C., Iorio, F., McFarland, J. M., Parts, L., & Vázquez, F. (2021) · Nature · doi:10.1038/d41586-021-00182-0 · Cited by 96
Self-citationCRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection
Gong, S., Zhang, S., Lü, F., Pan, W., Li, N., & Tang, B. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02533 · Cited by 100
Gogleva, A. A., Polychronopoulos, D., Pfeifer, M., Poroshin, V., Ughetto, M., Martin, M. J., Thorpe, H., Bornot, A., Smith, P. D., Sidders, B. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29292-7 · Cited by 95
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
